- Home
- REX vs MNKD Comparison
REX vs MNKD Comparison
Compare REX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | MNKD |
|---|---|---|
| Founded | 1980 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | REX | MNKD |
|---|---|---|
| Price | $39.95 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.84 |
| AVG Volume (30 Days) | 211.6K | ★ 4.2M |
| Earning Date | 12-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $650,487,000.00 | $348,966,000.00 |
| Revenue This Year | $18.22 | $27.44 |
| Revenue Next Year | N/A | $13.71 |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | 1.24 | ★ 22.23 |
| 52 Week Low | $31.00 | $2.23 |
| 52 Week High | $53.36 | $6.51 |
Technical Indicators
Market Signals| Indicator | REX | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 42.03 |
| Support Level | $39.04 | $2.91 |
| Resistance Level | $44.82 | $4.28 |
| Average True Range (ATR) | 1.49 | 0.18 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 2.65 | 29.02 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.